Rimini Street (RMNI) 10-Q 7 May 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	May 05, 2020
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Registrant Name	Rimini Street, Inc.
Entity Central Index Key	0001635282
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		68,186

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 57,632	$ 37,952
Restricted cash	333	436
Accounts receivable, net of allowance of $1,280 and $1,608, respectively	75,242	111,574
Deferred contract costs, current	11,779	11,754
Prepaid expenses and other	15,096	15,205
Total current assets	160,082	176,921
Long-term assets:
Property and equipment, net of accumulated depreciation and amortization of $10,138 and $9,847, respectively	3,566	3,667
Operating lease right-of-use assets	18,267	0
Deferred contract costs, noncurrent	16,693	16,295
Deposits and other	1,622	3,089
Deferred income taxes, net	1,107	1,248
Total assets	201,337	201,220
Current liabilities:
Accounts payable	6,194	2,303
Accrued compensation, benefits and commissions	23,905	27,918
Other accrued liabilities	19,123	23,347
Operating lease liabilities, current	4,060	0
Deferred revenue, current	195,800	205,771
Total current liabilities	249,082	259,339
Long-term liabilities:
Deferred revenue, noncurrent	26,854	29,727
Operating lease liabilities, noncurrent	15,018	0
Accrued PIK dividends payable	1,153	1,156
Other long-term liabilities	874	2,275
Total liabilities	292,981	292,497
Commitments and contingencies (Note 8)
Authorized 180 shares; issued and outstanding 156 shares and 155 shares as of March 31, 2020 and December 31, 2019, respectively. Liquidation preference of $156,401, net of discount of $22,368 and $155,231, net of discount of $23,915, as of March 31, 2020 and December 31, 2019, respectively.	134,033	131,316
Stockholders’ deficit:
Preferred stock; $0.0001 par value. Authorized 99,820 shares (excluding 180 shares of Series A Preferred Stock); no other series has been designated	0	0
Common stock; $0.0001 par value. Authorized 1,000,000 shares; issued and outstanding 68,032 and 67,503 shares as of March 31, 2020 and December 31, 2019, respectively	7	7
Additional paid-in capital	88,668	93,484
Accumulated other comprehensive loss	(2,242)	(1,429)
Accumulated deficit	(312,110)	(314,655)
Total stockholders' deficit	(225,677)	(222,593)
Total liabilities, redeemable preferred stock and stockholders' deficit	201,337	201,220
Allowance for Doubtful Accounts Receivable, Current	$ 1,280	$ 1,608

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for Doubtful Accounts Receivable, Current	$ 1,280		$ 1,608
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 10,138		$ 9,847
Temporary Equity, Shares Authorized	180,000		180,000
Temporary Equity, Shares Issued	156,000		155,000
Temporary Equity, Shares Outstanding	156,401		155,000
Temporary Equity, Liquidation Preference	$ 156,401		$ 155,231
Temporary Equity, Discount On Shares	$ 22,368	$ 23,915
Preferred Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001
Preferred Stock, Shares Authorized	99,820,000		99,820,000
Common Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001
Common Stock, Shares Authorized	1,000,000,000		1,000,000,000
Common Stock, Shares, Issued	68,032,000		67,503,000
Common Stock, Shares, Outstanding	68,032,000		67,503,000

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenue	$ 78,032	$ 65,873
Cost of revenue	30,199	23,837
Gross profit	47,833	42,036
Operating expenses:
Sales and marketing	28,412	23,955
General and administrative	12,001	12,988
Litigation costs and related recoveries:
Professional fees and other costs of litigation	2,752	2,041
Litigation appeal refunds	0	(12,775)
Insurance costs and recoveries, net	921	4,639
Litigation costs and related recoveries, net	3,673	(6,095)
Total operating expenses	44,086	30,848
Operating income	3,747	11,188
Non-operating income and (expenses):
Interest expense	(13)	(232)
Other income (expenses), net	(218)	43
Income before income taxes	3,516	10,999
Income tax expense	(971)	(705)
Net income	2,545	10,294
Other comprehensive income:
Foreign currency translation gain (loss)	(813)	1
Comprehensive income	1,732	10,295
Net loss attributable to common stockholders	$ (4,085)	$ 3,488
Net income (loss) per share attributable to common stockholders:
Basic (usd per share)	$ (0.06)	$ 0.05
Diluted (usd per share)	$ (0.06)	$ 0.05
Weighted average number of shares of Common Stock outstanding:
Basic (shares)	67,863,000	64,622,000
Diluted (shares)	67,863,000	69,101,000

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Private PlacementCommon Stock	Private PlacementAdditional Paid-in Capital
Beginning balance (shares) at Dec. 31, 2018		64,193
Stockholders' deficit, beginning of period at Dec. 31, 2018	$ (225,398)	$ 6	$ 108,347	$ (1,567)	$ (332,184)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash (shares)		667
Restricted stock units vested (shares)		138
Issuance of common stock (shares)		110				134
Exercise of stock options for cash		$ 1	782
Restricted stock units vested		0	0
Issuance of common stock		0	599			$ 0	$ 602
Stock based compensation expense			1,155
Accretion of discount on Series A Preferred Stock			(1,359)
Payable in cash			(3,593)
Payable in kind			(1,078)
Foreign currency translations gain (loss)	1			1
Net income	10,294				10,294
Stockholders' deficit, end of period at Mar. 31, 2019	(217,994)	$ 7	105,455	(1,566)	(321,890)
Ending balance (shares) at Mar. 31, 2019		65,242
Beginning balance (shares) at Dec. 31, 2019		67,503
Stockholders' deficit, beginning of period at Dec. 31, 2019	$ (222,593)	$ 7	93,484	(1,429)	(314,655)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash (shares)	304	304
Restricted stock units vested (shares)		225
Issuance of common stock (shares)		0				0
Exercise of stock options for cash		$ 0	304
Restricted stock units vested		0	0
Issuance of common stock		0	0			$ 0	$ 0
Stock based compensation expense			1,510
Accretion of discount on Series A Preferred Stock			(1,547)
Payable in cash			(3,910)
Payable in kind			(1,173)
Foreign currency translations gain (loss)	$ (813)			(813)
Net income	2,545				2,545
Stockholders' deficit, end of period at Mar. 31, 2020	$ (225,677)	$ 7	$ 88,668	$ (2,242)	$ (312,110)
Ending balance (shares) at Mar. 31, 2020		68,032

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 2,545	$ 10,294
Adjustments to reconcile net income to net cash provided by operating activities:
Accretion and amortization of debt discount and issuance costs	0	128
Stock-based compensation expense	1,510	1,155
Depreciation and amortization	449	494
Deferred income taxes	64	(26)
Amortization and accretion related to ROU assets	1,499	0
Other	0	141
Changes in operating assets and liabilities:
Accounts receivable	35,353	17,015
Prepaid expenses, deposits and other	1,141	(14,111)
Deferred contract costs	(423)	580
Accounts payable	3,963	(9,900)
Accrued compensation, benefits, commissions and other liabilities	(9,012)	886
Deferred revenue	(10,753)	(96)
Net cash provided by operating activities	26,336	6,560
CASH FLOWS USED IN INVESTING ACTIVITIES:
Capital expenditures	(524)	(381)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of Series A Preferred Stock and Common Stock	0	5,785
Principal payments on borrowings	0	(1,277)
Payments for deferred offering and financing costs	0	(294)
Payments of cash dividends on Series A Preferred Stock	(3,931)	(3,566)
Principal payments on capital leases	(56)	(197)
Proceeds from exercise of employee stock options	304	782
Net cash provided by (used in) financing activities	(3,683)	1,233
Effect of foreign currency translation changes	(2,552)	81
Net change in cash, cash equivalents and restricted cash	19,577	7,493
Cash, cash equivalents and restricted cash at beginning of period	38,388	25,206
Cash, cash equivalents and restricted cash at end of period	57,965	32,699
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	16	95
Cash paid for income taxes	897	647
Transaction costs	0	390
Accrued cash dividends	3,910	3,593
Accrued PIK dividends	1,173	1,078
Accretion of discount on Series A Preferred Stock	1,547	1,359
Issuance of Series A Preferred Stock for PIK dividends	1,070	1,062
Purchase of equipment under capital lease obligations	0	$ 206
Stock Issued, Noncash Transactions		134
Common Stock
Issuance of 85 shares of Common Stock for consent regarding Private Placements	0	$ 456
Redeemable Series A Preferred Stock
Fair value of 134 shares of Common Stock issued in 2019 for no consideration regarding their respective Private Placements	0	722
Original issuance discount on Series A Preferred Stock	$ 0	$ 325

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Statements of Cash Flows (Parenthetical) shares in Thousands	3 Months Ended
	Mar. 31, 2019shares
Common stock issued (shares)	134
Private Placement | Common Stock
Common stock issued (shares)	85

NATURE OF BUSINESS AND BASIS OF

NATURE OF BUSINESS AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	NATURE OF BUSINESS AND BASIS OF PRESENTATION Nature of Business Rimini Street, Inc. (the “Company”) is a global provider of enterprise software support services. The Company’s subscription-based software support products and services offer enterprise software licensees a choice of solutions that replace or supplement the support products and services offered by enterprise software vendors. Basis of Presentation and Consolidation The unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”). All significant intercompany balances and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, certain information and footnote disclosures required by U.S. GAAP for complete financial statements have been condensed or omitted in accordance with such rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2019, included in the Company’s 2019 Annual Report on Form 10-K as filed with the SEC on March 16, 2020 (the “2019 Form 10-K”). The accompanying condensed consolidated balance sheet and related disclosures as of December 31, 2019 have been derived from the Company’s audited financial statements. The Company’s financial condition as of March 31, 2020, and operating results for the three months ended March 31, 2020 are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the year ending December 31, 2020.

LIQUIDITY AND SIGNIFICANT ACCOU

LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES	LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES Liquidity As of March 31, 2020, the Company’s current liabilities exceeded its current assets by $89.0 million, and the Company earned net income of $2.5 million for the three months ended March 31, 2020. As of March 31, 2020, the Company had available cash, cash equivalents and restricted cash of $58.0 million. As of March 31, 2020, the Company's current liabilities included $195.8 million of deferred revenue whereby the historical costs of fulfilling the Company's commitments to provide services to its clients was approximately 39% of the related deferred revenue for the three months ended March 31, 2020. As discussed in Note 5, the Company completed a third private placement on June 20, 2019, which provided additional net proceeds of $3.0 million from the sale of 3,500 shares of 13.00% Series A Redeemable Convertible Preferred Stock, par value $0.0001 per share (the “ Series A Preferred Stock”) and 72,414 shares of Common Stock. On March 7, 2019, the Company completed a second private placement, which provided additional net cash proceeds of $5.0 million from the sale of 6,500 shares of the Series A Preferred Stock and 134,483 shares of Common Stock. In 2018, the Company had previously refinanced and repaid its Credit Facility (defined below) on July 19, 2018 through aggregate cash payments of $132.8 million that resulted in the termination of the Credit Facility. These cash payments were funded from the Initial Private Placement (together with cash-on-hand) discussed in Note 5 that resulted in cash proceeds of $133.0 million from the sale of 140,000 shares of Series A Preferred Stock and approximately 2.9 million shares of Common Stock. These refinancing arrangements did improve the Company’s liquidity and capital resources whereby cash dividends are payable at 10.0% per annum that will result in quarterly cash dividends ranging from $3.9 million to $4.3 million over the remaining initial 5-year period beginning on July 19, 2018, assuming all shares of Series A Preferred Stock remain outstanding, and thereafter, if not previously redeemed or converted, cash dividends will be payable at 13.0% per annum. Additionally, the Company is obligated to make operating and capital lease payments that are due within the next 12 months in the aggregate amount of $6.2 million. In March 2020, the World Health Organization declared the outbreak of a novel strain of the coronavirus (“COVID-19”) to be a pandemic. Assuming that, after the issuance date of these financial statements, the Company’s operations continue not to be significantly impacted by the COVID-19 pandemic, the Company believes that current cash, cash equivalents, restricted cash, and future cash flow from operating activities will be sufficient to meet the Company’s anticipated cash needs, including cash dividend requirements, working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of these financial statements. Use of Estimates The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, accounts receivable, valuation assumptions for stock options, deferred income taxes and the related valuation allowances, and the evaluation and measurement of contingencies. To the extent there are material differences between the Company’s estimates and actual results, the Company’s future consolidated results of operation may be affected. Recent Accounting Pronouncements Recently Adopted Standards. The following accounting standards were adopted during the first quarter of fiscal year 2020: In February 2016, Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-02, Leases , which requires organizations that lease assets (“lessees”) to recognize on the balance sheet the right of use ("ROU") assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months and to disclose key information about leasing arrangements. Under the new standard, both finance and operating leases will be required to be recognized on the balance sheet. Additional quantitative and qualitative disclosures, including significant judgments made by management, are also required. The Company adopted ASC 842 using the modified retrospective method on January 1, 2020. See Note 12 for the disclosure on the impact of adopting this standard. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires application of an impairment model known as the current expected credit loss (“CECL”) model to certain financial instruments held at amortized cost, including trade receivables. Using the CECL model, an entity recognizes an allowance for expected credit losses based on historical experience, current conditions, and forecasted information rather than the current methodology of delaying recognition of credit losses until it is probable loss has been incurred. The new guidance is effective for the Company in January 2020. The adoption of this guidance did not have a material impact on the Company's Consolidated Financial Statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement: Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements , which provides new guidance on disclosures related to fair value measurements. The guidance is intended to improve the effectiveness of the notes to financial statements by facilitating clearer communication, and it includes multiple new, eliminated and modified disclosure requirements. The guidance is effective for the Company in January 2020. The adoption of this guidance did not have an impact on the Company's Consolidated Financial Statements. In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which clarifies the accounting for implementation costs in cloud computing arrangements. The guidance aligns the requirements for capitalizing implementation costs in a hosting arrangement that is a service contract with the requirements for capitalization costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal-use software license. The new guidance is effective for the Company in January 2020. The adoption of this guidance did not have a material impact on the Company's Consolidated Financial Statements.

DEFERRED CONTRACT COSTS AND DEF

DEFERRED CONTRACT COSTS AND DEFERRED REVENUE	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
DEFERRED CONTRACT COSTS AND DEFERRED REVENUE	DEFERRED CONTRACT COSTS AND DEFERRED REVENUEActivity for deferred contract costs for the three months ended March 31, 2020 and 2019 is shown below (in thousands): 2020 2019 Deferred contract costs, current and noncurrent, as of the beginning of period $ 28,049 $ 27,080 Capitalized commissions during the period 3,753 2,418 Amortized deferred contract costs during the period (3,330) (2,997) Deferred contract costs, current and noncurrent, as of the end of period $ 28,472 $ 26,501 Deferred revenue activity for the three months ended March 31, 2020 and 2019 is shown below (in thousands): 2020 2019 Deferred revenue, current and noncurrent, as of beginning of period $ 235,498 $ 196,706 Billings, net 65,188 65,738 Revenue recognized (78,032) (65,873) Deferred revenue, current and noncurrent, as of end of period $ 222,654 $ 196,571 The transaction price allocated to the remaining performance obligations represents contracted revenue that has not yet been recognized. As of March 31, 2020, the remaining transaction price included in deferred revenue was $195.8 million in current and $26.9 million in noncurrent.

OTHER FINANCIAL INFORMATION

OTHER FINANCIAL INFORMATION	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
OTHER FINANCIAL INFORMATION	OTHER FINANCIAL INFORMATION Other Accrued Liabilities As of March 31, 2020 and December 31, 2019, other accrued liabilities consist of the following (in thousands): 2020 2019 Accrued sales and other taxes $ 2,626 $ 5,752 Accrued professional fees 4,380 4,367 Accrued dividends on Redeemable Series A Preferred Stock 3,874 3,889 Current maturities of capital lease obligations 204 222 Income taxes payable 688 1,091 Appeal proceeds payable to insurance company 5,309 4,388 Other accrued expenses 2,042 3,638 Total other accrued liabilities $ 19,123 $ 23,347 Interest Expense The components of interest expense are presented below (in thousands): Three Months Ended March 31, 2020 2019 Accretion expense for GP Sponsor note payable $ — $ 128 Interest on other borrowings 13 104 Total interest expense $ 13 $ 232 The note payable to GPIC Ltd, a Bermuda company (“GP Sponsor”), was paid off on June 28, 2019. See Note 9 for further information.

RESTRICTED STOCK UNITS, STOCK O

RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS	3 Months Ended
	Mar. 31, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS	RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS The Company’s stock option plans consist of the 2007 Stock Plan (the “2007 Plan”) and the 2013 Equity Incentive Plan, as amended and restated in July 2017 (the “2013 Plan”). The 2007 Plan and the 2013 Plan are collectively referred to as the “Stock Plans”. On February 25, 2020, the Board of Directors authorized an increase of approximately 2.7 million shares available for grant under the 2013 Plan. For additional information about the Stock Plans, please refer to Note 9 to the Company’s consolidated financial statements for the year ended December 31, 2019, included in the 2019 Form 10-K. The information presented below provides an update for activity under the Stock Plans for the three months ended March 31, 2020. Restricted Stock Units For the three months ended March 31, 2020, the Board of Directors granted restricted stock units (“RSUs”) under the 2013 Plan for an aggregate of approximately 75,000 shares of Common Stock to employees of the Company. These RSUs vest over periods ranging from 12 to 36 months from the respective grant dates and the awards are subject to forfeiture upon termination of employment or service on the Board of Directors. Based on the weighted average fair market value of the Common Stock on the date of grant of $4.85 per share, the aggregate fair value for the shares underlying the RSUs amounted to $0.4 million as of the grant date that will be recognized as compensation cost over the vesting period. Compensation expense related to RSUs of approximately $1.1 million and $0.5 million was recognized for the three months ended March 31, 2020 and 2019, respectively. As of March 31, 2020, the unrecognized expense of $8.5 million is expected to be charged to expense on a straight-line basis as the RSUs vest over a weighted-average period of approximately 2.3 years. Stock Options For the three months ended March 31, 2020, the Board of Directors granted stock options for the purchase of an aggregate of approximately 61,000 shares of Common Stock at an exercise prices that were equal to or greater than the fair market value of the Common Stock on the date of grant. These stock options generally vest annually for one-third of the awards and expire ten years after the grant date. The following table sets forth a summary of stock option activity under the Stock Plans for the three months ended March 31, 2020 (shares in thousands): Shares Price (1) Term (2) Outstanding, December 31, 2019 8,677 $ 4.55 4.9 Granted 61 4.69 Forfeited (93) 6.61 Expired (72) 5.62 Exercised (304) 1.00 Outstanding, March 31, 2020 (3)(4) 8,269 4.65 4.9 Vested, March 31, 2020 (3) 7,025 4.37 4.3 (1) Represents the weighted average exercise price. (2) Represents the weighted average remaining contractual term until the stock options expire. (3) As of March 31, 2020, the aggregate intrinsic value of all stock options outstanding was $7.4 million. As of March 31, 2020, the aggregate intrinsic value of vested stock options was $7.3 million. (4) The number of outstanding stock options that are not expected to ultimately vest due to forfeiture amounted to 0.1 million shares as of March 31, 2020. The following table presents activity affecting the total number of shares available for grant under the Stock Plans for the three months ended March 31, 2020 (in thousands): Available, December 31, 2019 2,885 Stock options granted (61) Restricted stock units granted (75) Expired options under Stock Plans 72 Forfeited options and restricted stock units under Stock Plans 148 Newly authorized by Board of Directors 2,700 Available, March 31, 2020 5,669 The aggregate fair value of approximately 61,000 stock options granted for the three months ended March 31, 2020 amounted to $0.1 million, or $1.68 per share as of the grant date. Fair value was computed using the Black-Scholes-Merton (“BSM”) method and will result in the recognition of compensation cost over the vesting period of the stock options. For the three months ended March 31, 2020, the fair value of each stock option grant under the Stock Plans was estimated on the date of grant using the BSM option-pricing model, with the following weighted-average assumptions: Expected life (in years) 6.0 Volatility 35% Dividend yield 0% Risk-free interest rate 1.30% Fair value per common share on date of grant $4.69 As of March 31, 2020 and December 31, 2019, total unrecognized compensation costs related to unvested stock options, net of estimated forfeitures, was $1.8 million and $2.2 million, respectively. As of March 31, 2020, the unrecognized costs are expected to be charged to expense on a straight-line basis over a weighted-average vesting period of approximately 1.7 years. Stock-Based Compensation Expense Stock-based compensation expense attributable to RSUs and stock options is classified as follows (in thousands): Three Months Ended 2020 2019 Cost of revenues $ 284 $ 209 Sales and marketing 623 341 General and administrative 603 605 Total $ 1,510 $ 1,155 Warrants As of March 31, 2020, warrants are outstanding for an aggregate of 18.1 million shares of Common Stock, including 3.4 million shares of Common Stock exercisable at $5.64 per share, and an aggregate of 14.7 million shares of Common Stock exercisable at $11.50 per share. For additional information about these warrants, please refer to Note 9 to the Company’s consolidated financial statements for the year ended December 31, 2019, included in the 2019 Form 10-K.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was passed into law, amending portions of relevant US tax laws, including the Tax Act discussed above. The CARES Act contains changes to corporate taxation, including among other things, adjusting net operating loss (NOL) limitations and carryback rules, refundable AMT credits, bonus depreciation and interest expense limitations. The CARES Act also provides for an Employee Retention Credit, a fully refundable payroll tax credit for certain eligible employers and the ability for all eligible employers to defer payment of the employer share of payroll taxes owed on wages paid for the period ending December 31, 2020 (such deferred payroll taxes are due in two installments: 50% by December 31, 2021 and 50% by December 31, 2022). The Company has elected to defer payroll tax payments, but it has not yet completed its evaluation of the remaining provisions. For the three months ended March 31, 2020 and 2019, our effective rate was 27.6% and 6.4% respectively. Our income tax expense was primarily attributable to earnings in foreign jurisdictions subject to income taxes. For the three months ended March 31, 2020 and 2019, no income tax expense was recorded in the United States as a result of historical net operating losses being incurred. The Company did not have any material changes to its conclusions regarding valuation allowances for deferred income tax assets or uncertain tax positions for the three months ended March 31, 2020 and 2019.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Series A Preferred Stock Dividends In connection with the issuance of Series A Preferred Stock on June 20, 2019, March 7, 2019 and July 19, 2018 as discussed in Note 5, the Company is obligated to pay Cash Dividends and issue additional shares of Series A Preferred Stock in settlement of PIK Dividends. From January 1, 2020 through July 19, 2023, the date that the Series A Preferred Stock is expected to be outstanding, estimated Cash Dividends and PIK Dividends required to be declared are as follows (in thousands): Year Ending December 31: Cash PIK Total 2020 $ 15,819 $ 4,746 $ 20,565 2021 16,299 4,890 21,189 2022 16,794 5,038 21,832 2023 9,455 2,837 12,292 Total $ 58,367 $ 17,511 $ 75,878 Retirement Plan The Company has defined contribution plans for both its U.S. and foreign employees. For certain of these plans, employees may contribute up to the statutory maximum, which is set by law each year. The plans also provide for employer contributions. The Company's contributions to these plans totaled $0.7 million for both the three months ended March 31, 2020 and 2019, respectively. Rimini I Litigation In January 2010, certain subsidiaries of Oracle Corporation (together with its subsidiaries individually and collectively, “Oracle”) filed a lawsuit, Oracle USA, Inc. et al. v. Rimini Street, Inc. et al. (United States District Court for the District of Nevada) (“Rimini I”), against the Company and its Chief Executive Officer, Seth Ravin, alleging that certain of the Company’s processes violated Oracle’s license agreements with its customers and that the Company committed acts of copyright infringement and violated other federal and state laws. The litigation involved the Company’s business processes and the manner in which the Company provided services to its clients. After completion of jury trial in 2015 and subsequent appeals, the final outcome of Rimini I was that Mr. Ravin was found not liable for any claims and the Company was found liable for only one of a dozen claims: “innocent infringement,” a jury finding that the Company did not know and had no reason to know that its former support processes were infringing. The jury also found that the infringement did not cause Oracle to suffer lost profits. The Company was ordered to pay a judgment of $124.4 million in 2016, which the Company promptly paid and then filed an appeal. With interest, attorneys’ fees and costs, the total judgment paid by the Company to Oracle after the completion of all appeals was approximately $89.9 million. A portion of such judgment was paid by the Company’s insurance carriers (for additional information on this topic, see Note 11 of the Company’s consolidated financial statements included in Part II, Item 8 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019). Proceeds from U.S. Supreme Court Decision The total judgment paid by the Company and its insurance carriers reflects a reduction of approximately $12.8 million that the Company had previously paid to Oracle (plus interest of $0.2 million), representing an award of non-taxable expenses to Oracle that was eventually overturned by unanimous decision of the U.S. Supreme Court in March 2019. As mandated by the U.S. Supreme Court, $13.0 million (the principal amount plus post-judgment interest) was refunded to the Company by Oracle in April 2019. A portion of the funds received by the Company will be shared on a pro rata basis with an insurance company that had paid for part of the judgment and a portion of Rimini’s defense costs. This reimbursement will reflect a deduction of the costs of the Company’s past and pending appeal and remand proceedings. As a result of the U.S. Supreme Court decision, the Company recognized a recovery of the non-taxable expenses for $12.8 million and interest income of $0.2 million for the year ended December 31, 2019, excluding any contractual amounts due to the insurance company. The Company recognized costs o f $0.9 million for the three months ended March 31, 2020 , as the Company revised its current estimate of the amounts owed to the insurance company (for portions of all previously-paid judgments refunded to the Company on appeal, including the proceeds from the U.S. Supreme Court Decision) to $5.3 million as of March 31, 2020 (for additional information on this topic, see Note 11 of the Company’s consolidated financial statements included in Part II, Item 8 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019). Injunction Following post-trial motions, the District Court entered a permanent injunction prohibiting the Company from using certain processes, including processes adjudicated as infringing at trial, that the Company ceased using no later than July 2014, which the Company subsequently appealed to the United States Court of Appeals for the Ninth Circuit (“Court of Appeals”), arguing on appeal that the injunction is vague and contains overly-broad language that could be read to cover some of the Company’s current business practices that were not adjudicated to be infringing at trial and that the injunction should not have been issued under applicable law. After multiple rounds of remand and appeal, in August 2019, the Court of Appeals entered an Order affirming the permanent injunction. However, the Court of Appeals agreed that the injunction was overbroad in two respects and instructed the District Court to remove the restriction on “local hosting” of J.D. Edwards and Siebel software and the prohibition against “accessing” J.D. Edwards and Siebel software source code. A copy of the injunction is publicly available in the case docket. As a result of the injunction, the Company expects to incur additional expenses in the range of 1% to 2% of revenue for additional labor costs because, as drafted, the injunction contains language that could be read to cover some current support practices that are being litigated in the “Rimini II” lawsuit (as defined below) and that have not been found to be infringing. In February 2019, Oracle filed a motion to reopen discovery in Rimini I in a purported effort to investigate whether the Company is complying with the injunction. The deadline for expert discovery in such effort is scheduled to close on June 5, 2020, and the deadline for Oracle to file any motion for order to show cause related to alleged contempt is June 24, 2020. These deadlines are subject to change by court order, and actual deadlines could be extended. Rimini II Litigation In October 2014, the Company filed a separate lawsuit, Rimini Street Inc. v. Oracle Int’l Corp. (United States District Court for the District of Nevada), against Oracle seeking a declaratory judgment that the Company’s revised development processes, in use since at least July 2014, do not infringe certain Oracle copyrights (“Rimini II”). Oracle filed counterclaims alleging copyright infringement, which included (i) substantially the same allegations asserted in Rimini I, but limited to clients not addressed in Rimini I, and (ii) new allegations that the Company’s revised support processes also infringe Oracle copyrights. Oracle’s counterclaims also included allegations of violation of the Lanham Act, intentional interference with prospective economic advantage, breach of contract and inducing breach of contract, unfair competition, unjust enrichment/restitution and violation of the Digital Millennium Copyright Act. Oracle also sought an accounting. In December 2016, the Company filed an amended complaint against Oracle, adding claims for intentional interference with contract, intentional interference with prospective economic advantage, violation of the Nevada Deceptive Trade Practices Act, violation of the Lanham Act, and violation of California Business & Professions Code §17200 et seq. Oracle then amended its counterclaims to include requesting declaratory judgment of no intentional interference with contractual relations, no intentional interference with prospective economic advantage, and no violation of California Business & Professions Code §17200 et seq. By stipulation of the parties, the District Court granted the Company’s motion to file the Company’s third amended complaint to add claims arising from Oracle’s purported revocation of the Company’s access to its support websites on behalf of the Company’s clients, which was filed and served in May 2017. In September 2017, the District Court issued an order granting in part and denying in part the Company’s motion to dismiss Oracle’s third amended counterclaims. The District Court granted the Company’s motion to dismiss Oracle’s intentional interference with prospective economic advantage and unjust enrichment counterclaims. In November 2017, the District Court issued an order granting in part and denying in part Oracle’s motion to dismiss the Company’s third amended complaint. The District Court granted Oracle’s motion to dismiss as to the Company’s third cause of action for a declaratory judgment that Oracle has engaged in copyright misuse, fifth cause of action for intentional interference with prospective economic advantage; sixth cause of action for a violation of Nevada’s Deceptive Trade Practices Act under the “bait and switch” provision of NRS § 598.0917; and seventh cause of action for violation of the Lanham Act. The District Court denied Oracle’s motion as to the Company’s causes of action for intentional interference with contractual relations, violation of Nevada Deceptive Trade Practices Act, under the “false and misleading” provision of NRS §598.0915(8) and unfair competition. Fact discovery with respect to the above action substantially ended in March 2018, and expert discovery ended in September 2018. In October 2018, the Company and Oracle each filed motions for summary judgment. Briefing on the parties’ motions for summary judgment was completed in December 2018, and the Company awaits the District Court’s ruling on those motions. There is currently no trial date scheduled, and while the Company does not expect a trial to occur in this matter earlier than 2022, the trial could occur earlier or later than that. At this time, the Company does not have sufficient information regarding possible recovery by the Company in connection with the Company’s claims against Oracle or possible damages exposure for the counterclaims asserted by Oracle. Both parties are seeking injunctive relief in addition to monetary damages in this matter. As a result, an estimate of the range of loss cannot be reasonably determined. The Company also believes that an award for damages is not probable, so no accrual has been made as of March 31, 2020. Other Litigation From time to time, the Company may be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of these ordinary course matters will not have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on the Company because of judgment, defense and settlement costs, diversion of management resources and other factors. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies . Legal fees are expensed as incurred. Governmental Inquiry In March 2018, the Company received a federal grand jury subpoena, issued from the United States District Court for the Northern District of California, requesting the Company to produce certain documents relating to specified support and related operational practices. The Company fully cooperated with this inquiry and the related document requests by April 2019 and has received no further requests since that date. Liquidated Damages The Company enters into agreements with clients that contain provisions related to liquidated damages that would be triggered in the event that the Company is no longer able to provide services to these clients. The maximum cash payments related to these liquidated damages is approximately $20.9 million and $22.7 million as of March 31, 2020 and December 31, 2019, respectively. To date, the Company has not incurred any costs as a result of such provisions and has not accrued any liabilities related to such provisions in these unaudited condensed consolidated financial statements.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Upon consummation of the merger with GP Investments Acquisition Corp. ("GPIA") in May 2017, an outstanding note payable to GP Sponsor with an initial face amount of approximately $3.0 million was assumed by the Company. This note was originally non-interest bearing and was not due and payable until the outstanding principal balance under the former Credit Facility was less than $95.0 million. At the inception of this note, the maturity date was expected to occur in June 2020 based on the scheduled principal payments under the former Credit Facility. Interest was initially imputed under this note payable at the rate of 15.0% per annum. The net carrying value of this note payable was $2.4 million as of December 31, 2018, and the Company recognized accretion expense of $0.1 million for the three months ended March 31, 2019, respectively. This note payable was amended twice in 2018, which resulted in further changes to the effective interest rate and maturity date. The second amendment to the loan agreement was effective on December 21, 2018, and provided for an extension of the maturity date from January 4, 2019 to June 28, 2019. In addition, the parties agreed that the note payable would retroactively bear interest at 13.0% per annum from July 19, 2018 through the maturity date. Total retroactive interest amounted to $0.2 million which is accounted for as debt discounts and issuance costs (“DDIC”) that was being accreted through the maturity date. In addition, the second amendment provided for monthly principal payments starting in December 2018 of approximately $0.4 million plus accrued interest. In December 2018, the Company made a payment of $0.6 million, primarily consisting of payment of retroactive interest of $0.2 million and the first monthly principal payment of $0.4 million. The Company made principal and interest payments totaling $2.7 million through June 28, 2019, of which $1.3 million was paid during the three months ended March 31, 2019. The effective interest rate for accretion of DDIC was 26.4% for the period from December 21, 2018 through June 28, 2019. The note was paid off on June 28, 2019. An affiliate of Adams Street Partners ("ASP") is a member of the Company’s Board of Directors. As of March 31, 2020, ASP owned approximately 34.8% of the Company’s issued and outstanding shares of Common Stock. In July 2018, ASP acquired 19,209 shares of Series A Preferred Stock and approximately 0.4 million shares of Common Stock issued in the Initial Private Placement discussed in Note 5 for total consideration of approximately $19.2 million. As of March 31, 2020, ASP had voting control of approximately 30.7% of the Company’s issued and outstanding shares of Common Stock, including voting rights associated with the 20,049 shares of Series A Preferred Stock. Prior to termination on July 19, 2018 of the Company's amended Credit Facility, ASP owned a $10.0 million indirect interest in the amended Credit Facility. For the three months ended March 31, 2020 and 2019, the Company recognized revenue for software support services provided to certain ASP investees for an aggregate of $0.2 million and $0.3 million, respectively. Accounts receivable included no amount due from ASP investees for software support services as of March 31, 2020 and December 31, 2019, respectively.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE We compute earnings per share in accordance with ASC Topic 260, Earnings per Share (“ASC 260”), which requires earnings per share for each class of stock to be calculated using the two-class method. The holders of Series A Preferred Stock are entitled to participate in Common Stock dividends, if and when declared, on a one-to-one per-share basis. Accordingly, in periods in which the Company has net income, earnings per share will be computed using the two-class method whereby the pro rata dividends on Common Stock that are also distributable to the holders of Series A Preferred Stock will be deducted from earnings applicable to common stockholders, regardless of whether a dividend is declared for such undistributed earnings. Under the two-class method, earnings for the reporting period are allocated between the holders of our Common Stock and the Series A Preferred Stock based on their respective participation rights in undistributed earnings. Basic earnings per Common Stock share is computed by dividing net income attributable to common stockholders by the weighted average number of shares of basic Common Stock outstanding. Net income allocated to the holders of our Series A Preferred Stock is calculated based on the shareholders’ proportionate share of the weighted average shares of Common Stock outstanding on an if-converted basis. Diluted earnings per Common Stock share is calculated by adjusting the basic earnings per Common Stock share for the effects of potential dilutive Common Stock shares outstanding such as stock options, restricted stock units and warrants. For the three months ended March 31, 2020 and 2019, basic and diluted net earnings per share of Common Stock were computed by dividing the net income attributable to common stockholders by the weighted average number of common shares outstanding during the respective periods. The following table sets forth the computation of basic and diluted net income attributable to common stockholders for the three months ended March 31, 2020 and 2019 (in thousands, except per share amounts): Three Months Ended March 31, 2020 2019 Income attributable to common stockholders: Net income $ 2,545 $ 10,294 Dividends and accretion related to Series A Preferred Stock: Cash dividends declared (3,910) (3,593) PIK dividends declared (1,173) (1,078) Accretion of discount (1,547) (1,359) (4,085) 4,264 Undistributed earnings allocated using the two-class method — (776) Net loss attributable to common stockholders $ (4,085) $ 3,488 Three Months Ended March 31, 2020 2019 Weighted average number of shares of Common Stock outstanding 67,863 64,622 Additional shares outstanding if Series A Preferred Stock is converted to Common Stock 15,639 14,370 Total shares outstanding if Series A Preferred Stock is converted to Common Stock 83,502 78,992 Percentage of shares allocable to Series A Preferred Stock 18.7 % 18.2 % Weighted average number of shares of Common Stock outstanding: Basic 67,863 64,622 Effect of dilutive securities: Warrants — — Stock options — 4,390 Restricted stock units — 89 Diluted 67,863 69,101 Net (loss) earnings per share attributable to common stockholders: Basic $ (0.06) $ 0.05 Diluted $ (0.06) $ 0.05 For the three months ended March 31, 2020, basic and diluted loss per share attributable to common stockholders were the same because all Common Stock equivalents were anti-dilutive. As of March 31, 2020, the following potential Common Stock equivalents were excluded from the computation of diluted net loss per share for the respective periods ending on these dates since the impact of inclusion was anti-dilutive (in thousands): 2020 Series A Preferred Stock 15,640 Restricted stock units 2,703 Stock options 8,269 Warrants 18,128 Total 44,740

FINANCIAL INSTRUMENTS AND SIGNI

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS	3 Months Ended
	Mar. 31, 2020
Investments, All Other Investments [Abstract]
FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS	FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Fair Value Measurements Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts, and considers assumptions that market participants would use when pricing the asset or liability. Additional information on fair value measurements is included in Note 13 to the Company’s consolidated financial statements for the year ended December 31, 2019, included in the 2019 Form 10-K. As discussed in Note 5, the fair value for our Series A Preferred Stock issuances on June 20, 2019, March 7, 2019 and July 19, 2018 were determined to be $3.0 million, $5.3 million and $126.8 million, respectively, which were utilized to determine the basis for allocating the net proceeds. The fair value was determined by utilizing a combination of a discounted cash flow methodology related to funds generated by the Series A Preferred Stock, along with the BSM option-pricing model in relation to the conversion feature. Key assumptions applied for the discounted cash flow and BSM analysis included (i) three different scenarios whereby the Series A Preferred Stock would remain outstanding between 4 and 5 years along with a probability weighting assigned to each scenario, (ii) an implied yield of the Series A Preferred Stock ranging from 20.9% to 22.9% calibrated to the transaction values as of June 20, 2019, March 7, 2019 and July 19, 2018, respectively, (iii) risk-free interest rates of 1.72%, 2.44% and 2.8% and (iv) historical volatility of 30.0%. The Company’s policy is to recognize asset or liability transfers among Level 1, Level 2 and Level 3 as of the actual date of the events or change in circumstances that caused the transfer. As of March 31, 2020, the Company does not have any assets or liabilities that are carried at fair value on a recurring basis. The carrying amounts of the Company’s financial instruments including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities approximate fair values due to their short-term maturities. Based on borrowing rates currently available to the Company for debt with similar terms, the carrying value of capital lease obligations approximate fair value as of the respective balance sheet dates. Significant Concentrations The Company attributes revenues to geographic regions based on the location of its clients’ contracting entity. The following table shows revenues by geographic region (in thousands): Three Months Ended 2020 2019 United States of America $ 47,446 $ 42,717 International 30,586 23,156 Total $ 78,032 $ 65,873 No clients represented more than 10% of revenue for the three months ended March 31, 2020 or 2019. As of March 31, 2020 and December 31, 2019, no clients accounted for more than 10% of total net accounts receivable. Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and accounts receivable. The Company maintains its cash, cash equivalents and restricted cash at high-quality financial institutions, primarily in the United States of America. Deposits, including those held in foreign branches of global banks, may exceed the amount of insurance provided on such deposits. As of March 31, 2020 and December 31, 2019, the Company had cash, cash equivalents and restricted cash with a single financial institution for an aggregate of $46.2 million and $33.1 million, respectively. As of March 31, 2020 and December 31, 2019, the Company had restricted cash of $0.3 million and $0.4 million, respectively. The Company has never experienced any losses related to these balances. Generally, credit risk with respect to accounts receivable is diversified due to the number of entities comprising the Company’s client base and their dispersion across different geographies and industries. The Company performs ongoing credit evaluations on certain clients and generally does not require collateral on accounts receivable. The Company maintains reserves for potential bad debts and historically such losses are generally not significant.

ASC 842 ADOPTION IMPACT

ASC 842 ADOPTION IMPACT	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
ASC 842 ADOPTION IMPACT	Effective at the start of fiscal 2020, the Company adopted the provisions and expanded disclosure requirements described in Topic 842. The Company adopted the standard using the prospective method. Accordingly, the results for the prior comparable periods were not adjusted to conform to the current period measurement or recognition of results. The Company has operating leases for real estate and equipment with an option to renew the leases for up to one month to five years. Some of the leases include the option to terminate the leases upon 30-days notice with a penalty. The Company's leases have remaining lease terms from May 2020 to January 2027. The Company's lease agreements may include renewal or termination options for varying periods that are generally at the Company's discretion. The Company's lease term only includes those periods related to renewal options we believe are reasonably certain to exercise. The Company generally does not include these renewal options as it is not reasonably certain to renew at the lease commencement date. This determination is based on consideration of certain economic, strategic and other factors that the Company evaluates at lease commencement date and reevaluates throughout the lease term. Some leases also include options to terminate the leases and we only include those periods beyond the termination date if we are reasonably certain not to exercise the termination option. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance and tax payments. The variable portion of lease payments is not included in our ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred and are included in lease expenses recorded in selling and administrative expenses on the Consolidated Statements of Operations. We have lease agreements with both lease and non-lease components that are treated as a single lease component for all underlying asset classes. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses. We have elected to apply the short-term lease exception for all underlying asset classes. That is, leases with a term of 12 months or less are not recognized on the balance sheet, but rather expensed on a straight-line basis over the lease term. Our leases do not include significant restrictions or covenants, and residual value guarantees are generally not included within our operating leases. As of March 31, 2020, we did not have any material additional operating leases that have not yet commenced. The components of lease expense and supplemental balance sheet information were as follows (in thousands): Three months ended March 31, 2020 Operating lease expense related to ROU assets and liabilities $ 1,499 Other lease expense 318 Total lease expense $ 1,817 Other information related leases was as follows (in thousands): Supplemental Balance Sheet Information March 31, 2020 Operating lease right-of-use assets, noncurrent $ 18,267 Operating lease liabilities, current $ 4,060 Operating lease liabilities, noncurrent 15,018 Total operating lease liabilities $ 19,078 As of January 1, 2020, the Company had total operating lease right-of use assets of $18.8 million and total operating lease liabilities of $20.0 million. Weighted Average Remaining Lease Term Years Operating leases 5.03 Weighted Average Discount Rate Operating leases 11.0 % Maturities of operating lease liabilities as of March 31, 2020 were as follows (in thousands): Year ending March 31: 2021 $ 5,909 2022 5,439 2023 3,822 2024 2,753 2025 2,604 Thereafter 4,430 Total future undiscounted lease payments 24,957 Less imputed interest (5,879) Total $ 19,078 For the three months ended March 31, 2020, the Company paid $1.5 million for operating lease liabilities. Maturities of operating leases accounted for under ASC 840 as of December 31, 2019 were as follows (in thousands):

LIQUIDITY AND SIGNIFICANT ACC_2

LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Nature of Business	Nature of Business
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”). All significant intercompany balances and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, certain information and footnote disclosures required by U.S. GAAP for complete financial statements have been condensed or omitted in accordance with such rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2019, included in the Company’s 2019 Annual Report on Form 10-K as filed with the SEC on March 16, 2020 (the “2019 Form 10-K”). The accompanying condensed consolidated balance sheet and related disclosures as of December 31, 2019 have been derived from the Company’s audited financial statements. The Company’s financial condition as of March 31, 2020, and operating results for the three months ended March 31, 2020 are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the year ending December 31, 2020.
Use of Estimates	Use of Estimates The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, accounts receivable, valuation assumptions for stock options, deferred income taxes and the related valuation allowances, and the evaluation and measurement of contingencies. To the extent there are material differences between the Company’s estimates and actual results, the Company’s future consolidated results of operation may be affected.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Standards. The following accounting standards were adopted during the first quarter of fiscal year 2020: In February 2016, Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-02, Leases , which requires organizations that lease assets (“lessees”) to recognize on the balance sheet the right of use ("ROU") assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months and to disclose key information about leasing arrangements. Under the new standard, both finance and operating leases will be required to be recognized on the balance sheet. Additional quantitative and qualitative disclosures, including significant judgments made by management, are also required. The Company adopted ASC 842 using the modified retrospective method on January 1, 2020. See Note 12 for the disclosure on the impact of adopting this standard. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires application of an impairment model known as the current expected credit loss (“CECL”) model to certain financial instruments held at amortized cost, including trade receivables. Using the CECL model, an entity recognizes an allowance for expected credit losses based on historical experience, current conditions, and forecasted information rather than the current methodology of delaying recognition of credit losses until it is probable loss has been incurred. The new guidance is effective for the Company in January 2020. The adoption of this guidance did not have a material impact on the Company's Consolidated Financial Statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement: Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements , which provides new guidance on disclosures related to fair value measurements. The guidance is intended to improve the effectiveness of the notes to financial statements by facilitating clearer communication, and it includes multiple new, eliminated and modified disclosure requirements. The guidance is effective for the Company in January 2020. The adoption of this guidance did not have an impact on the Company's Consolidated Financial Statements. In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which clarifies the accounting for implementation costs in cloud computing arrangements. The guidance aligns the requirements for capitalizing implementation costs in a hosting arrangement that is a service contract with the requirements for capitalization costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal-use software license. The new guidance is effective for the Company in January 2020. The adoption of this guidance did not have a material impact on the Company's Consolidated Financial Statements.
Earnings Per Share	We compute earnings per share in accordance with ASC Topic 260, Earnings per Share (“ASC 260”), which requires earnings per share for each class of stock to be calculated using the two-class method. The holders of Series A Preferred Stock are entitled to participate in Common Stock dividends, if and when declared, on a one-to-one per-share basis. Accordingly, in periods in which the Company has net income, earnings per share will be computed using the two-class method whereby the pro rata dividends on Common Stock that are also distributable to the holders of Series A Preferred Stock will be deducted from earnings applicable to common stockholders, regardless of whether a dividend is declared for such undistributed earnings. Under the two-class method, earnings for the reporting period are allocated between the holders of our Common Stock and the Series A Preferred Stock based on their respective participation rights in undistributed earnings.

DEFERRED CONTRACT COSTS AND D_2

DEFERRED CONTRACT COSTS AND DEFERRED REVENUE (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Contract liabilities	Activity for deferred contract costs for the three months ended March 31, 2020 and 2019 is shown below (in thousands): 2020 2019 Deferred contract costs, current and noncurrent, as of the beginning of period $ 28,049 $ 27,080 Capitalized commissions during the period 3,753 2,418 Amortized deferred contract costs during the period (3,330) (2,997) Deferred contract costs, current and noncurrent, as of the end of period $ 28,472 $ 26,501 Deferred revenue activity for the three months ended March 31, 2020 and 2019 is shown below (in thousands): 2020 2019 Deferred revenue, current and noncurrent, as of beginning of period $ 235,498 $ 196,706 Billings, net 65,188 65,738 Revenue recognized (78,032) (65,873) Deferred revenue, current and noncurrent, as of end of period $ 222,654 $ 196,571

OTHER FINANCIAL INFORMATION (Ta

OTHER FINANCIAL INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Other Accrued Liabilities	As of March 31, 2020 and December 31, 2019, other accrued liabilities consist of the following (in thousands): 2020 2019 Accrued sales and other taxes $ 2,626 $ 5,752 Accrued professional fees 4,380 4,367 Accrued dividends on Redeemable Series A Preferred Stock 3,874 3,889 Current maturities of capital lease obligations 204 222 Income taxes payable 688 1,091 Appeal proceeds payable to insurance company 5,309 4,388 Other accrued expenses 2,042 3,638 Total other accrued liabilities $ 19,123 $ 23,347
Schedule of Interest Expense	The components of interest expense are presented below (in thousands): Three Months Ended March 31, 2020 2019 Accretion expense for GP Sponsor note payable $ — $ 128 Interest on other borrowings 13 104 Total interest expense $ 13 $ 232

REDEEMABLE SERIES A PREFERRED S

REDEEMABLE SERIES A PREFERRED STOCK (Tables)	3 Months Ended
	Mar. 31, 2020
Temporary Equity Disclosure [Abstract]
Allocation Private Placement Proceeds	The allocation of the net proceeds as of the Closing Date, along with changes in the net carrying value of the Series A Preferred Stock through March 31, 2020 are set forth below (dollars in thousands): Series A Preferred Stock Common Convertible Shares Amount Stock Notes Total Fair value on July 19, 2018: Series A Preferred Stock 140,000 $ 126,763 (1) $ — $ — $ 126,763 Common Stock — — 20,131 (2) — 20,131 Convertible Notes — — — — — Total 140,000 $ 126,763 $ 20,131 $ — $ 146,894 Relative fair value allocation on July 19, 2018 Aggregate cash proceeds on July 19, 2018 140,000 $ 114,773 (3) $ 18,227 (3) $ — $ 133,000 Incremental and direct costs — (3,994) (4) (634) (4) — (4,628) Net carrying value on July 19, 2018 140,000 $ 110,779 $ 17,593 $ — $ 128,372 _________________ 1. The liquidation preference for each share of Series A Preferred Stock on the closing date for the Initial Private Placement was $1,000 per for an aggregate liquidation preference of $140.0 million. The estimated fair value of the Series A Preferred Stock was approximately $126.8 million on July 19, 2018, which is the basis for allocation of the net proceeds. Please refer to Note 11 for further discussion of the valuation methodology employed. 2. The fair value of the issuance of approximately 2.9 million shares of the Common Stock was based on the last closing price of $6.95 per share on the date prior to closing the transaction. 3. The aggregate cash proceeds of $133.0 million on July 19, 2018 were allocated pro rata based on the fair value of all consideration issued. 4. Incremental and direct costs of the Initial Private Placement were allocated pro rata based on the fair value of all consideration issued. Such costs include financial advisory and professional fees of $2.7 million that were incurred by the Company, and due diligence and professional fees incurred by the investors of $1.9 million. Series A Preferred Stock Common Convertible Shares Amount Stock Notes Total Fair value on March 7, 2019: Series A Preferred Stock 6,500 $ 5,313 (1) $ — $ — $ 5,313 Common Stock — — 722 (2) — 722 Convertible Notes — — — — — Total 6,500 $ 5,313 $ 722 $ — $ 6,035 Relative fair value allocation on March 7, 2019: Aggregate cash proceeds on March 7, 2019 6,500 $ 5,093 (3) $ 692 (3) $ — $ 5,785 Incremental and direct costs — (661) (4) (90) (4) — (751) Net carrying value on March 7, 2019 6,500 $ 4,432 $ 602 $ — $ 5,034 (1) The liquidation preference for each share of Series A Preferred Stock on the closing date for the March 2019 Private Placement was $1,000 per share for an aggregate liquidation preference of $6.5 million. The estimated fair value of the Series A Preferred Stock was approximately $5.3 million on March 7, 2019, which is the basis for allocation of the net proceeds. Please refer to Note 11 for further discussion of the valuation methodology employed. (2) The fair value of the issuance of approximately 134,483 shares of the Common Stock was based on the closing price of $5.37 per share on the date prior to closing of the transaction. (3) The aggregate cash proceeds of $5.8 million on March 7, 2019 were allocated pro rata based on the fair value of all consideration issued. (4) Incremental and direct costs related to the March 2019 Private Placement were allocated pro rata based on the fair value of all consideration issued. Such costs included the issuance of 85,000 shares of Common Stock to the Initial Private Placement investors in the Series A Preferred Stock for their consent of approximately $0.5 million and financial advisory and professional fees that were incurred of approximately $0.3 million that were either paid or accrued directly by the Company as of March 31, 2019. Series A Preferred Stock Common Convertible Shares Amount Stock Notes Total Fair value on June 20, 2019: Series A Preferred Stock 3,500 $ 2,997 (1) $ — $ — $ 2,997 Common Stock — — 376 (2) — 376 Convertible Notes — — — — — Total 3,500 $ 2,997 $ 376 $ — $ 3,373 Relative fair value allocation on June 20, 2019: Aggregate cash proceeds on June 20, 2019 3,500 $ 2,954 (3) $ 371 (3) $ — $ 3,325 Incremental and direct costs — (301) (4) (38) (4) — (339) Net carrying value on June 20, 2019 3,500 $ 2,653 $ 333 $ — $ 2,986 (1) The liquidation preference for each share of Series A Preferred Stock on the closing date for the June 2019 Private Placement was $1,000 per share for an aggregate liquidation preference of $3.5 million. The estimated fair value of the Series A Preferred Stock was approximately $3.0 million on June 20, 2019, which is the basis for allocation of the net proceeds. Please refer to Note 11 for further discussion of the valuation methodology employed. (2) The fair value of the issuance of approximately 72,414 shares of the Common Stock was based on the closing price of $5.19 per share on the date prior to closing of the transaction. (3) The aggregate cash proceeds of $3.3 million on June 20, 2019 were allocated pro rata based on the fair value of all consideration issued. (4) Incremental and direct costs related to the June 2019 Private Placement were allocated pro rata based on the fair value of all consideration issued. Such costs included the issuance of 35,000 shares of Common Stock to the Initial Private Placement investors in the Series A Preferred Stock for their consent of approximately $0.2 million and financial advisory and professional fees that were incurred of approximately $0.2 million that were either paid or accrued directly by the Company as of June 30, 2019.
Temporary Equity	The changes in the net carrying value of Series A Preferred Stock from December 31, 2019 to March 31, 2020 are set forth below (dollars in thousands): Series A Preferred Stock Shares Amount Net carrying value as of December 31, 2019 155,231 $ 131,316 Issuance of shares to settle PIK Dividends on January 2, 2020 1,170 1,170 Accretion of discount for the three months ended March 31, 2020 — 1,547 Net carrying value as of March 31, 2020 156,401 $ 134,033
Dividends Declared	Presented below is a summary of total and per share dividends declared through March 31, 2020 (dollars in thousands, except per share amounts): Dividends Payable in: Total Dividends Cash PIK Dividends Per Share Dividends payable as of December 31, 2019 $ 3,889 $ 1,156 $ 5,045 $ 32.50 Cash Dividends 10% per annum 3,910 — 3,910 25.00 PIK Dividends 3% per annum — 1,167 1,167 7.46 Fractional PIK shares settled for cash 6 — 6 0.04 Less dividends settled January 2, 2020 (3,931) (1,170) (5,101) (32.61) Dividends payable as of March 31, 2020 $ 3,874 $ 1,153 $ 5,027 $ 32.14 Year Ending December 31: Cash PIK Total 2020 $ 15,819 $ 4,746 $ 20,565 2021 16,299 4,890 21,189 2022 16,794 5,038 21,832 2023 9,455 2,837 12,292 Total $ 58,367 $ 17,511 $ 75,878

RESTRICTED STOCK UNITS, STOCK_2

RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock Option Activity	The following table sets forth a summary of stock option activity under the Stock Plans for the three months ended March 31, 2020 (shares in thousands): Shares Price (1) Term (2) Outstanding, December 31, 2019 8,677 $ 4.55 4.9 Granted 61 4.69 Forfeited (93) 6.61 Expired (72) 5.62 Exercised (304) 1.00 Outstanding, March 31, 2020 (3)(4) 8,269 4.65 4.9 Vested, March 31, 2020 (3) 7,025 4.37 4.3 (1) Represents the weighted average exercise price. (2) Represents the weighted average remaining contractual term until the stock options expire. (3) As of March 31, 2020, the aggregate intrinsic value of all stock options outstanding was $7.4 million. As of March 31, 2020, the aggregate intrinsic value of vested stock options was $7.3 million. (4) The number of outstanding stock options that are not expected to ultimately vest due to forfeiture amounted to 0.1 million shares as of March 31, 2020.
Schedule of Shares Available for Grant Activity	The following table presents activity affecting the total number of shares available for grant under the Stock Plans for the three months ended March 31, 2020 (in thousands): Available, December 31, 2019 2,885 Stock options granted (61) Restricted stock units granted (75) Expired options under Stock Plans 72 Forfeited options and restricted stock units under Stock Plans 148 Newly authorized by Board of Directors 2,700 Available, March 31, 2020 5,669
Schedule of Assumptions of Fair Value of Stock Option Grants	For the three months ended March 31, 2020, the fair value of each stock option grant under the Stock Plans was estimated on the date of grant using the BSM option-pricing model, with the following weighted-average assumptions: Expected life (in years) 6.0 Volatility 35% Dividend yield 0% Risk-free interest rate 1.30% Fair value per common share on date of grant $4.69
Schedule of Stock-based Compensation Expense	Stock-based compensation expense attributable to RSUs and stock options is classified as follows (in thousands): Three Months Ended 2020 2019 Cost of revenues $ 284 $ 209 Sales and marketing 623 341 General and administrative 603 605 Total $ 1,510 $ 1,155

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Dividends Declared	Presented below is a summary of total and per share dividends declared through March 31, 2020 (dollars in thousands, except per share amounts): Dividends Payable in: Total Dividends Cash PIK Dividends Per Share Dividends payable as of December 31, 2019 $ 3,889 $ 1,156 $ 5,045 $ 32.50 Cash Dividends 10% per annum 3,910 — 3,910 25.00 PIK Dividends 3% per annum — 1,167 1,167 7.46 Fractional PIK shares settled for cash 6 — 6 0.04 Less dividends settled January 2, 2020 (3,931) (1,170) (5,101) (32.61) Dividends payable as of March 31, 2020 $ 3,874 $ 1,153 $ 5,027 $ 32.14 Year Ending December 31: Cash PIK Total 2020 $ 15,819 $ 4,746 $ 20,565 2021 16,299 4,890 21,189 2022 16,794 5,038 21,832 2023 9,455 2,837 12,292 Total $ 58,367 $ 17,511 $ 75,878

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted net income attributable to common stockholders for the three months ended March 31, 2020 and 2019 (in thousands, except per share amounts): Three Months Ended March 31, 2020 2019 Income attributable to common stockholders: Net income $ 2,545 $ 10,294 Dividends and accretion related to Series A Preferred Stock: Cash dividends declared (3,910) (3,593) PIK dividends declared (1,173) (1,078) Accretion of discount (1,547) (1,359) (4,085) 4,264 Undistributed earnings allocated using the two-class method — (776) Net loss attributable to common stockholders $ (4,085) $ 3,488 Three Months Ended March 31, 2020 2019 Weighted average number of shares of Common Stock outstanding 67,863 64,622 Additional shares outstanding if Series A Preferred Stock is converted to Common Stock 15,639 14,370 Total shares outstanding if Series A Preferred Stock is converted to Common Stock 83,502 78,992 Percentage of shares allocable to Series A Preferred Stock 18.7 % 18.2 % Weighted average number of shares of Common Stock outstanding: Basic 67,863 64,622 Effect of dilutive securities: Warrants — — Stock options — 4,390 Restricted stock units — 89 Diluted 67,863 69,101 Net (loss) earnings per share attributable to common stockholders: Basic $ (0.06) $ 0.05 Diluted $ (0.06) $ 0.05
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	As of March 31, 2020, the following potential Common Stock equivalents were excluded from the computation of diluted net loss per share for the respective periods ending on these dates since the impact of inclusion was anti-dilutive (in thousands): 2020 Series A Preferred Stock 15,640 Restricted stock units 2,703 Stock options 8,269 Warrants 18,128 Total 44,740

FINANCIAL INSTRUMENTS AND SIG_2

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables)	3 Months Ended
	Mar. 31, 2020
Investments, All Other Investments [Abstract]
Schedule of Revenues by Geographic Regions	The Company attributes revenues to geographic regions based on the location of its clients’ contracting entity. The following table shows revenues by geographic region (in thousands): Three Months Ended 2020 2019 United States of America $ 47,446 $ 42,717 International 30,586 23,156 Total $ 78,032 $ 65,873

ASC 842 ADOPTION IMPACT (Tables

ASC 842 ADOPTION IMPACT (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Components of lease expense	The components of lease expense and supplemental balance sheet information were as follows (in thousands): Three months ended March 31, 2020 Operating lease expense related to ROU assets and liabilities $ 1,499 Other lease expense 318 Total lease expense $ 1,817 Other information related leases was as follows (in thousands): Supplemental Balance Sheet Information March 31, 2020 Operating lease right-of-use assets, noncurrent $ 18,267 Operating lease liabilities, current $ 4,060 Operating lease liabilities, noncurrent 15,018 Total operating lease liabilities $ 19,078 As of January 1, 2020, the Company had total operating lease right-of use assets of $18.8 million and total operating lease liabilities of $20.0 million. Weighted Average Remaining Lease Term Years Operating leases 5.03 Weighted Average Discount Rate Operating leases 11.0 %
Maturities of operating lease liabilities	Maturities of operating lease liabilities as of March 31, 2020 were as follows (in thousands): Year ending March 31: 2021 $ 5,909 2022 5,439 2023 3,822 2024 2,753 2025 2,604 Thereafter 4,430 Total future undiscounted lease payments 24,957 Less imputed interest (5,879) Total $ 19,078

LIQUIDITY AND SIGNIFICANT ACC_3

LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 20, 2019	Mar. 07, 2019	Jul. 19, 2018	Jul. 31, 2018	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Significant Accounting Policies Disclosure [Line Items]
Working capital deficit					$ 89,000
Net income (loss) attributable to parent					2,545	$ 10,294
Cash, cash equivalents, restricted cash and restricted cash equivalents					57,965	$ 32,699	$ 38,388	$ 25,206
Deferred revenue, current					$ 195,800
Historical cost of goods and services (as a percent of deferred revenue)					39.00%
Gross cash proceeds			$ 133,000
Cash dividends payable (as a percent)			10.00%
Dividends Payable					$ 75,878
Initial dividend period (in years)			5 years
Cash dividends payable after five year period (as a percent)			13.00%
Capital leases - future minimum payments due in the next twelve months					$ 6,200
Minimum
Significant Accounting Policies Disclosure [Line Items]
Dividends Payable			$ 3,900
Maximum
Significant Accounting Policies Disclosure [Line Items]
Dividends Payable			4,300
Revolving Credit Facility
Significant Accounting Policies Disclosure [Line Items]
Repayments of lines of credit			$ 132,800
Common Stock
Significant Accounting Policies Disclosure [Line Items]
New stock issued during period (shares)	72,414	134,483	2,900,000		0	110,000
Series A Preferred Stock
Significant Accounting Policies Disclosure [Line Items]
Dividend rate (as a percent)					13.00%
Temporary equity, par value (usd per share)					$ 0.0001
New stock issued during period (shares)			140,000	19,209
Dividends Payable					$ 5,027		$ 5,045
Private Placement
Significant Accounting Policies Disclosure [Line Items]
Consideration received	$ 2,986	$ 5,034	$ 128,372
Private Placement | Common Stock
Significant Accounting Policies Disclosure [Line Items]
Sale of stock (shares)	72,414	134,483
New stock issued during period (shares)	72,414	134,483			0	134,000
Private Placement | Series A Preferred Stock
Significant Accounting Policies Disclosure [Line Items]
Sale of stock (shares)	3,500	6,500	140,000

DEFERRED CONTRACT COSTS AND D_3

DEFERRED CONTRACT COSTS AND DEFERRED REVENUE (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Capitalized Contract Cost, Net [Abstract]
Deferred contract costs, current and noncurrent, as of the beginning of period	$ 28,049	$ 27,080
Capitalized commissions during the period	3,753	2,418
Amortized deferred contract costs during the period	(3,330)	(2,997)
Deferred contract costs, current and noncurrent, as of the end of period	28,472	26,501
Change in Contract with Customer, Liability [Abstract]
Deferred revenue, current and noncurrent, as of beginning of period	235,498	196,706
Billings, net	65,188	65,738
Revenue recognized	(78,032)	(65,873)
Deferred revenue, current and noncurrent, as of end of period	222,654	$ 196,571
Deferred revenue, current	195,800		$ 205,771
Deferred revenue, noncurrent	$ 26,854		$ 29,727

OTHER FINANCIAL INFORMATION - O

OTHER FINANCIAL INFORMATION - Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued sales and other taxes	$ 2,626	$ 5,752
Accrued professional fees	4,380	4,367
Accrued dividends on Redeemable Series A Preferred Stock	3,874	3,889
Current maturities of capital lease obligations	204	222
Income taxes payable	688	1,091
Appeal proceeds payable to insurance company	5,309	4,388
Other accrued expenses	2,042	3,638
Total other accrued liabilities	$ 19,123	$ 23,347

OTHER FINANCIAL INFORMATION - I

OTHER FINANCIAL INFORMATION - Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accretion expense for GP Sponsor note payable	$ 0	$ 128
Interest on other borrowings	13	104
Total interest expense	$ 13	$ 232

REDEEMABLE SERIES A PREFERRED_2

REDEEMABLE SERIES A PREFERRED STOCK - Narrative (Details) $ / shares in Units, $ in Thousands	Apr. 01, 2020shares	Jun. 20, 2019USD ($)$ / sharesshares	Mar. 07, 2019USD ($)$ / sharesshares	Jul. 19, 2018USD ($)$ / sharesshares	Jul. 31, 2018shares	Mar. 31, 2020USD ($)dayeffective_year$ / sharesshares	Mar. 31, 2019USD ($)shares	Dec. 31, 2019shares
Securities Purchase Agreements [Abstract]
Net proceeds from issuance of Series A Preferred Stock and Common Stock						$ 0	$ 5,785
Discount on shares				$ 7,000
Line of credit unpaid transaction costs				2,700
Stock issuance costs						$ 0	$ 294
Professional fees				$ 200
Certificate Of Designations [Abstract]
Shares authorized (shares) | shares						180,000		180,000
Number of years dividend will be effective | effective_year						5
Dividends payable, current						$ 3,900
Dividends payable, non-current						$ 1,200
Temporary equity, liquidation preference (usd per share) | $ / shares				$ 1,000		$ 10
Temporary equity liquidation preference (shares) | shares						15,600,000
Temporary stock outstanding (shares) | shares						156,401		155,000
Temporary equity, shares issued upon conversion (shares) | shares						1
Threshold trading days | day						30
Threshold consecutive trading days						45 days
Threshold stock price, minimum (usd per share) | $ / shares						$ 11.50
Consecutive trading days prior to conversion date | day						60
Liquidation preference in case of liquidation, dissolution, or winding up of company						$ 80,000
Temporary equity, liquidation preference per share, in event of liquidation, dissolution, or winding up of company (usd per share) | $ / shares						$ 1,000
Outstanding percentage, indebtedness restriction (as a percent)						95.00%
Funded Debt
Securities Purchase Agreements [Abstract]
Repayments of lines of credit				$ 132,800
Private Placement
Securities Purchase Agreements [Abstract]
Net proceeds from issuance of Series A Preferred Stock and Common Stock		$ 3,325	$ 5,785	133,000
Discount on shares		200	700
Incremental and direct transaction costs		339	751	4,628
Stock issuance costs		$ 300	$ 800	2,700
Discount on shares (as a percent)		5.00%	11.00%
Consideration received		$ 2,986	$ 5,034	$ 128,372
Incremental and direct costs, shares issued, cost		$ 200	$ 500
Series A Preferred Stock
Securities Purchase Agreements [Abstract]
New stock issued during period (shares) | shares				140,000	19,209
Certificate Of Designations [Abstract]
Dividend rate (as a percent)						13.00%
Series A Preferred Stock | Subsequent Event
Certificate Of Designations [Abstract]
Temporary equity issued for paid-in-kind dividends (shares) | shares	1,153
Series A Preferred Stock | Private Placement
Securities Purchase Agreements [Abstract]
Sale of stock (shares) | shares		3,500	6,500	140,000
Net proceeds from issuance of Series A Preferred Stock and Common Stock		$ 2,954	$ 5,093	$ 114,773
Incremental and direct transaction costs		$ 301	$ 661	$ 3,994
Certificate Of Designations [Abstract]
Temporary equity, liquidation preference (usd per share) | $ / shares		$ 1,000	$ 1,000
Temporary stock outstanding (shares) | shares						156,401		155,231
Common Stock
Securities Purchase Agreements [Abstract]
New stock issued during period (shares) | shares		72,414	134,483	2,900,000		0	110,000
Common Stock | Private Placement
Securities Purchase Agreements [Abstract]
Sale of stock (shares) | shares		72,414	134,483
New stock issued during period (shares) | shares		72,414	134,483			0	134,000
Net proceeds from issuance of Series A Preferred Stock and Common Stock		$ 371	$ 692	$ 18,227
Incremental and direct transaction costs		$ 38	$ 90	634
Incremental and direct costs (shares) | shares		35,000	85,000
Due Diligence And Professional Fees | Private Placement
Securities Purchase Agreements [Abstract]
Incremental and direct transaction costs		$ 200	$ 300	$ 1,900			$ 300
Cash Dividend
Certificate Of Designations [Abstract]
Dividend rate (as a percent)						10.00%
Paid-In-Kind Dividend
Certificate Of Designations [Abstract]
Dividend rate (as a percent)						3.00%

REDEEMABLE SERIES A PREFERRED_3

REDEEMABLE SERIES A PREFERRED STOCK - Series A Preferred Stock Summary (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 20, 2019	Mar. 07, 2019	Jul. 19, 2018	Jul. 31, 2018	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Temporary Equity [Line Items]
Net proceeds from issuance of Series A Preferred Stock and Common Stock					$ 0	$ 5,785
Net carrying value					134,033		$ 131,316
Common stock issued					$ 7		7
Footnotes [Abstract]
Temporary equity, liquidation preference (usd per share)			$ 1,000		$ 10
Temporary Equity, Liquidation Preference	$ 3,500	$ 6,500	$ 140,000		$ 156,401		$ 155,231
Net proceeds from issuance of Series A Preferred Stock and Common Stock					0	5,785
Series A Preferred Stock
Footnotes [Abstract]
New stock issued during period (shares)			140,000	19,209
Private Placement
Temporary Equity [Line Items]
Temporary stock issued	2,997	5,313	$ 126,763
Issuance of common stock	3,373	6,035	146,894
Net proceeds from issuance of Series A Preferred Stock and Common Stock	3,325	5,785	133,000
Incremental and direct costs	(339)	(751)	(4,628)
Consideration received	2,986	5,034	128,372
Footnotes [Abstract]
Temporary stock issued	2,997	5,313	126,763
Net proceeds from issuance of Series A Preferred Stock and Common Stock	3,325	5,785	133,000
Incremental and direct costs, shares issued, cost	200	500
Incremental and direct transaction costs	$ 339	$ 751	$ 4,628
Private Placement | Series A Preferred Stock
Temporary Equity [Line Items]
Temporary stock issued (shares)	3,500	6,500	140,000
Temporary stock issued	$ 2,997	$ 5,313	$ 126,763
Net proceeds from issuance of Series A Preferred Stock and Common Stock	2,954	5,093	114,773
Incremental and direct costs	(301)	(661)	(3,994)
Net carrying value	$ 2,653	$ 4,432	110,779
Footnotes [Abstract]
Temporary equity, liquidation preference (usd per share)	$ 1,000	$ 1,000
Temporary stock issued	$ 2,997	$ 5,313	126,763
Net proceeds from issuance of Series A Preferred Stock and Common Stock	2,954	5,093	114,773
Incremental and direct transaction costs	$ 301	$ 661	$ 3,994
Common Stock
Temporary Equity [Line Items]
Issuance of common stock					$ 0	$ 0
Footnotes [Abstract]
New stock issued during period (shares)	72,414	134,483	2,900,000		0	110,000
Shares issued (usd per share)	$ 5.19	$ 5.37	$ 6.95
Common Stock | Private Placement
Temporary Equity [Line Items]
Issuance of common stock	$ 376	$ 722	$ 20,131		$ 0	$ 0
Net proceeds from issuance of Series A Preferred Stock and Common Stock	371	692	18,227
Incremental and direct costs	(38)	(90)	(634)
Common stock issued	$ 333	$ 602	17,593
Footnotes [Abstract]
New stock issued during period (shares)	72,414	134,483			0	134,000
Net proceeds from issuance of Series A Preferred Stock and Common Stock	$ 371	$ 692	18,227
Incremental and direct costs (shares)	35,000	85,000
Incremental and direct transaction costs	$ 38	$ 90	634
Due Diligence And Professional Fees | Private Placement
Temporary Equity [Line Items]
Incremental and direct costs	(200)	(300)	(1,900)			$ (300)
Footnotes [Abstract]
Incremental and direct transaction costs	$ 200	$ 300	1,900			$ 300
Financial Advisor And Professional Fees | Private Placement
Temporary Equity [Line Items]
Incremental and direct costs			(2,700)
Footnotes [Abstract]
Incremental and direct transaction costs			$ 2,700

REDEEMABLE SERIES A PREFERRED_4

REDEEMABLE SERIES A PREFERRED STOCK - Change in Value of Temporary Equity (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)shares
Increase (Decrease) in Temporary Equity [Roll Forward]
Temporary equity, beginning balance (shares)	155,000
Temporary equity, ending balance (shares)	156,401
Private Placement | Series A Preferred Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Temporary equity, beginning balance (shares)	155,231
Temporary equity, beginning balance | $	$ 131,316
Temporary equity issued for paid-in-kind dividends (shares)	1,170
Temporary equity issued for paid-in-kind dividends | $	$ 1,170
Accretion of discount | $	$ 1,547
Temporary equity, ending balance (shares)	156,401
Temporary equity, ending balance | $	$ 134,033

REDEEMABLE SERIES A PREFERRED_5

REDEEMABLE SERIES A PREFERRED STOCK - Dividends (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 02, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Dividends Payable [Roll Forward]
Dividends, cash		$ 3,910	$ 3,593
Dividends, paid-in-kind		1,173	1,078
Dividends payable end of period		$ 75,878
Cash Dividend
Dividends Payable [Roll Forward]
Dividend rate (as a percent)		10.00%
Dividends payable end of period		$ 58,367
Paid-In-Kind Dividend
Dividends Payable [Roll Forward]
Dividend rate (as a percent)		3.00%
Dividends payable end of period		$ 17,511
Series A Preferred Stock
Dividends Payable [Roll Forward]
Dividends payable start of period		$ 5,045
Dividend rate (as a percent)		13.00%
Dividends payable (usd per share)		$ 32.14		$ 32.50
Payments of dividends	$ (5,101)
Dividends, cash paid (usd per share)	$ (32.61)
Dividends payable end of period		$ 5,027
Series A Preferred Stock | Cash Dividend
Dividends Payable [Roll Forward]
Dividends payable start of period		$ 3,889
Dividends, cash			3,910
Dividends			3,910
Dividends payable (usd per share)		$ 25
Payments of dividends	$ (3,931)
Dividends payable end of period		$ 3,874
Series A Preferred Stock | Paid-In-Kind Dividend
Dividends Payable [Roll Forward]
Dividends payable start of period		$ 1,156
Dividends, paid-in-kind			1,167
Dividends			1,167
Dividends payable (usd per share)		$ 7.46
Payments of dividends	$ (1,170)
Dividends payable end of period		$ 1,153
Series A Preferred Stock | Fractional Shares
Dividends Payable [Roll Forward]
Dividends, cash			6
Dividends			$ 6
Dividends payable (usd per share)		$ 0.04

RESTRICTED STOCK UNITS, STOCK_3

RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Feb. 25, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock available for grant newly authorized by Board of Directors (shares)		2,700
Restricted Stock Units [Abstract]
Share price of common stock on date of grant of RSUs (USD per share)		$ 4.85
Aggregate fair value of shares underlying RSU's		$ 400
Stock-based compensation expense		1,510	$ 1,155
Compensation costs not yet recognized of nonvested awards		$ 8,500
Stock Options [Abstract]
Stock options granted in period (shares)		61
Warrants [Abstract]
Warrants outstanding (shares)		18,100
Exercise Price $5.64
Warrants [Abstract]
Warrants outstanding (shares)		3,400
Exercise price of warrants (USD per share)		$ 5.64
Exercise Price $11.50
Warrants [Abstract]
Warrants outstanding (shares)		14,700
Exercise price of warrants (USD per share)		$ 11.50
Restricted stock units
Restricted Stock Units [Abstract]
Stock-based compensation expense		$ 1,100	$ 500
Period for recognition of compensation costs not yet recognized related to nonvested awards		2 years 3 months 18 days
Stock Options [Abstract]
Period for recognition of compensation costs not yet recognized related to nonvested awards		2 years 3 months 18 days
Stock options
Restricted Stock Units [Abstract]
Period for recognition of compensation costs not yet recognized related to nonvested awards		1 year 8 months 12 days
Stock Options [Abstract]
Stock options granted in period (shares)		61
Fair value of stock options granted		$ 100
Weighted-average grant date fair value per share of options granted in period (usd per share)		$ 1.68
Unrecognized compensation costs		$ 1,800		$ 2,200
Period for recognition of compensation costs not yet recognized related to nonvested awards		1 year 8 months 12 days
2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock available for grant newly authorized by Board of Directors (shares)	2,700
2013 Plan | Restricted stock units
Restricted Stock Units [Abstract]
Restricted stock units granted in period (shares)		75
2013 Plan | Restricted stock units | Minimum
Restricted Stock Units [Abstract]
Award vesting period		12 months
2013 Plan | Restricted stock units | Maximum
Restricted Stock Units [Abstract]
Award vesting period		36 months
2013 Plan | Stock options
Stock Options [Abstract]
Award vesting rights (percent)		33.33%
Stock Plans
Stock Options [Abstract]
Term of vested options (years)		10 years

RESTRICTED STOCK UNITS, STOCK_4

RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Shares
Outstanding at beginning of period (shares)	8,677
Granted (shares)	61
Forfeited (shares)	(93)
Expired (shares)	(72)
Exercised (shares)	(304)
Outstanding at end of period (shares)	8,269	8,677
Vested at end of period (shares)	7,025
Price
Outstanding at beginning of period (USD per share)	$ 4.55
Granted (USD per share)	4.69
Forfeited (USD per share)	6.61
Expired (USD per share)	5.62
Exercised (USD per share)	1
Outstanding at end of period (USD per share)	4.65	$ 4.55
Vested (USD per share)	$ 4.37
Term
Term of outstanding options	4 years 10 months 24 days	4 years 10 months 24 days
Term of vested options (years)	4 years 3 months 18 days
Aggregate intrinsic value of stock options outstanding	$ 7.4
Aggregate intrinsic value of vested stock options	$ 7.3
Outstanding stock options not expected to vest due to forfeitures (shares)	100

RESTRICTED STOCK UNITS, STOCK_5

RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Shares Available for Grant (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2020shares
Shares Available for Grant [Roll Forward]
Available at beginning of period (shares)	2,885
Stock options granted (shares)	(61)
Restricted stock units granted (shares)	(75)
Expired options under Stock Plans (shares)	72
Forfeited options and restricted stock units under Stock Plans (shares)	148
Newly authorized by Board of Directors (shares)	2,700
Available at end of period (shares)	5,669

RESTRICTED STOCK UNITS, STOCK_6

RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Assumptions of Fair Value of Stock Option Grants (Details)	3 Months Ended
	Mar. 31, 2020$ / shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected life (in years)	6 years
Volatility (as a percent)	35.00%
Dividend yield (as a percent)	0.00%
Risk-free interest rate (as a percent)	1.30%
Fair value per common share on date of grant (USD per share)	$ 4.69

RESTRICTED STOCK UNITS, STOCK_7

RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,510	$ 1,155
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	284	209
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	623	341
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 603	$ 605

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Investments, Owned, Federal Income Tax Note [Line Items]
Federal statutory income tax rate (as a percent)	27.60%	6.40%
Income tax expense (benefit)	$ 971,000	$ 705,000
Domestic Tax Authority
Investments, Owned, Federal Income Tax Note [Line Items]
Income tax expense (benefit)	$ 0	$ 0

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Series A Preferred Stock Dividends (Details) $ in Thousands	Mar. 31, 2020USD ($)
Dividends Payable [Line Items]
2020	$ 20,565
2021	21,189
2022	21,832
2023	12,292
Total	75,878
Cash Dividend
Dividends Payable [Line Items]
2020	15,819
2021	16,299
2022	16,794
2023	9,455
Total	58,367
Paid-In-Kind Dividend
Dividends Payable [Line Items]
2020	4,746
2021	4,890
2022	5,038
2023	2,837
Total	$ 17,511

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($) $ in Millions	Jul. 19, 2018	Mar. 31, 2019	Mar. 31, 2020	Dec. 31, 2019
Loss Contingencies [Line Items]
Employer contribution		$ 0.7
Professional fees	$ 0.2
Current carrying value of guarantor obligations			$ 20.9	$ 22.7

RELATED PARTY TRANSACTIONS - Na

RELATED PARTY TRANSACTIONS - Narrative (Details) - USD ($)	Jul. 19, 2018	Dec. 31, 2018	Jul. 31, 2018	Mar. 31, 2020	Mar. 31, 2019	Jun. 28, 2019	Jun. 28, 2019	Jul. 18, 2018	May 31, 2017
Related Party Transaction [Line Items]
Face amount (less than)				$ 95,000,000
Notes payable due to related party		$ 2,400,000
Stated interest rate (as a percent)	13.00%
Interest expense due to related party	$ 200,000	200,000			$ 100,000
Periodic payment amount of principal		400,000
Repayments of related party debt					1,300,000		$ 2,700,000
Interest rate						26.40%
Debt Instrument, Periodic Payment, Interest		$ 600,000
Common Class A Stock
Related Party Transaction [Line Items]
New stock issued during period (shares)			400,000
Series A Preferred Stock
Related Party Transaction [Line Items]
New stock issued during period (shares)	140,000		19,209
GP Sponsor
Related Party Transaction [Line Items]
Notes payable									$ 3,000,000
Stated interest rate (as a percent)	15.00%
Adams Street Partners
Related Party Transaction [Line Items]
Carrying value of preferred stock outstanding								$ 10,000,000
Expenses from transactions with related party				$ 200,000	$ 300,000
Private Placements | Affiliated Entity
Related Party Transaction [Line Items]
Total consideration			$ 19,200,000

EARNINGS (LOSS) PER SHARE - Ear

EARNINGS (LOSS) PER SHARE - Earnings per share (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2019USD ($)$ / sharesshares
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Temporary equity, conversion ratio	1
Net income | $	$ 2,545	$ 10,294
Cash dividends declared | $	(3,910)	(3,593)
PIK dividends declared | $	(1,173)	(1,078)
Accretion of discount | $	(1,547)	(1,359)
Net (loss) income after dividends and accretion | $	(4,085)	4,264
Undistributed earnings allocated using the two-class method | $	0	(776)
Net loss attributable to common stockholders | $	$ (4,085)	$ 3,488
Weighted average number of shares outstanding, basic (shares) | shares	67,863,000	64,622,000
Additional shares outstanding if Series A Preferred Stock is converted to Common Stock (shares) | shares	15,639,000	14,370,000
Total shares outstanding if Series A Preferred Stock is converted to Common Stock (shares) | shares	83,502,000	78,992,000
Percentage of shares allocable to Series A Preferred Stock (percent)	18.70%	18.20%
Weighted average number of shares outstanding, diluted (shares) | shares	67,863,000	69,101,000
Basic (usd per share) | $ / shares	$ (0.06)	$ 0.05
Diluted (usd per share) | $ / shares	$ (0.06)	$ 0.05
Warrants
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Weighted average number of shares outstanding, diluted (shares) | shares	0	0
Stock options
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Weighted average number of shares outstanding, diluted (shares) | shares	0	4,390,000
Restricted stock units
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Weighted average number of shares outstanding, diluted (shares) | shares	0	89,000

EARNINGS (LOSS) PER SHARE - Sum

EARNINGS (LOSS) PER SHARE - Summary (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2020shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (shares)	44,740
Series A Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (shares)	15,640
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (shares)	2,703
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (shares)	8,269
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (shares)	18,128

FINANCIAL INSTRUMENTS AND SIG_3

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Narrative (Details) $ in Thousands	Jun. 20, 2019USD ($)	Mar. 07, 2019USD ($)	Jul. 19, 2018USD ($)	Mar. 31, 2020USD ($)year	Dec. 31, 2019USD ($)	Sep. 19, 2018
Concentration Risk [Line Items]
Cash and cash equivalents				$ 57,632	$ 37,952
Single Financial Institution
Concentration Risk [Line Items]
Cash and cash equivalents				46,200	33,100
Current restricted cash				$ 300	$ 400
Private Placement
Concentration Risk [Line Items]
Temporary stock issued	$ 2,997	$ 5,313	$ 126,763
Series A Preferred Stock | Private Placement
Concentration Risk [Line Items]
Temporary stock issued	$ 2,997	$ 5,313	$ 126,763
Measurement Input, Expected Term | Series A Preferred Stock | Minimum
Concentration Risk [Line Items]
Measurement input (as a percent) | year				4
Measurement Input, Expected Term | Series A Preferred Stock | Maximum
Concentration Risk [Line Items]
Measurement input (as a percent) | year				5
Measurement Input, Implied Yield | Series A Preferred Stock | Minimum
Concentration Risk [Line Items]
Measurement input (as a percent)				0.209
Measurement Input, Implied Yield | Series A Preferred Stock | Maximum
Concentration Risk [Line Items]
Measurement input (as a percent)				0.229
Measurement Input, Risk Free Interest Rate | Series A Preferred Stock
Concentration Risk [Line Items]
Measurement input (as a percent)	0.0172	0.0244				0.028
Measurement Input, Price Volatility | Series A Preferred Stock
Concentration Risk [Line Items]
Measurement input (as a percent)				0.300

FINANCIAL INSTRUMENTS AND SIG_4

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 78,032	$ 65,873
United States of America
Disaggregation of Revenue [Line Items]
Revenue	47,446	42,717
International
Disaggregation of Revenue [Line Items]
Revenue	$ 30,586	$ 23,156

ASC 842 ADOPTION IMPACT - Narra

ASC 842 ADOPTION IMPACT - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)
Leases [Abstract]
Operating lease payments	$ 1.5

ASC 842 ADOPTION IMPACT - Compo

ASC 842 ADOPTION IMPACT - Components of lease expense (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Leases [Abstract]
Operating lease expense related to ROU assets and liabilities	$ 1,499
Other lease expense	318
Total lease expense	$ 1,817

ASC 842 ADOPTION IMPACT - Suppl

ASC 842 ADOPTION IMPACT - Supplemental balance sheet information (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Leases [Abstract]
Operating lease right-of-use assets	$ 18,267	$ 0
Operating lease liabilities, current	4,060	0
Operating lease liabilities, noncurrent	15,018	$ 0
Operating Lease, Liability, Total	$ 19,078
Weighted average remaining lease term, operating leases (years)			5 years 10 days
Weighted average discount rate, operating leases (as a percent)			11.00%

ASC 842 ADOPTION IMPACT - Matur

ASC 842 ADOPTION IMPACT - Maturities of lease liability (Details) $ in Thousands	Mar. 31, 2020USD ($)
Leases [Abstract]
2021	$ 5,909
2022	5,439
2023	3,822
2024	2,753
2025	2,604
Thereafter	4,430
Total future undiscounted lease payments	24,957
Less imputed interest	(5,879)
Total	$ 19,078